Cipher Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Cipher Pharmaceuticals Il CEO è Craig Mull, nominato in Jul2019, ha un mandato di 5.33 anni. possiede direttamente 3.19% delle azioni della società, per un valore di € 7.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 3.5 anni.

Informazioni chiave

Craig Mull

Amministratore delegato

US$1.0m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	5.3yrs
Proprietà del CEO	3.2%
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Craig Mull

5.3yrs

Mandato

US$1,045,700

Compensazione

Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and its Interim Chief Executive Officer since July 29, 2019, served as its President. Mr. Mu...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Craig Mull	Interim CEO & Chairman of the Board	5.3yrs	US$1.05m	3.19% € 7.0m
Bryan Jacobs	Chief Financial Officer	2.3yrs	US$391.35k	0.020% € 43.0k
Emilio Presti	Director of Sales & Marketing	2.8yrs	Nessun dato	Nessun dato
Hamed Ghanei	Chief Business Officer	less than a year	Nessun dato	Nessun dato

2.5yrs

Durata media

Gestione esperta: Il team dirigenziale di PHE è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Craig Mull	Interim CEO & Chairman of the Board	5.7yrs	US$1.05m	3.19% € 7.0m
Harold Wolkin	Lead Independent Director	8.3yrs	US$73.49k	1.43% € 3.2m
Douglas Deeth	Independent Director	1.4yrs	US$65.57k	Nessun dato
Hubert Walinski	Independent Director	1.4yrs	US$62.57k	Nessun dato

3.5yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PHE sono considerati esperti (durata media dell'incarico 3.5 anni).

Cipher Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

Less than half of directors are independent

Independent Director recently sold €56k worth of stock

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Recent updates

Investor sentiment deteriorates as stock falls 17%

Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023)

New major risk - Earnings quality

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 21%

Investor sentiment improves as stock rises 18%

Cipher Pharmaceuticals Inc. Announces CFO Changes

Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023)

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

Investor sentiment improves as stock rises 25%

Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022)

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022)

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022)

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022)

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021)

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold €56k worth of stock

Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)

Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021)

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)

Cipher Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 18, 2021

Cipher Pharmaceuticals Receives Arbitration Award on Trulance

New 90-day high: €0.74

Third quarter 2020 earnings released: EPS US$0.06

Revenue beats expectations

New 90-day low: €0.59

Cipher Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: €0.64

Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director

New 90-day low: €0.69

New 90-day low - €0.71

First half earnings released

New 90-day high - €0.95

New 90-day high - €0.87

AMMINISTRATORE DELEGATO

Mandato

Compensazione